Acarix - Glimpsing the West
2021-10-04 10:15:00
Redeye reviews its assessment of Acarix, acknowledging the clinical and regulatory progress for the CADScor device and the catalysts ahead in the form of acquired reimbursement, high-volume orders, and establishment in the US market. We hike our fair value range as our reassessment suggests a more optimistic take on the case.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/